Aligos Therapeutics, Inc. ALGS 深 沪
等待开盘 06-26 09:30:00 美东时间
5.48
-0.095
-1.70%
华盛通- 最 高5.94
- 今 开5.63
- 成交量 5.17万股
- 最 低 5.255
- 昨 收 5.575
- 总市值 23.40万
- 52周最高 13.6892
- 市盈率 静 --
- 换手率 121.14%
- 52周最低 4.80
- 委 比 10.22%
- 总股本 4.27万
- 历史最高 46.80
- 量 比 0.69
- 振 幅 12.29%
- 历史最低 0.3482
- 每 手 1
- 风险率 1.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for April 16th
MYSE: 280% | Myseum shares are trading higher. The company announced a rebrand to Myseum.AI. ALGS: 48% | Aligos Therapeutics shares are trading higher after the company announced that it has entered into
04-16 19:26
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
今年涨幅超过1400%，“罕见病第一股”北海康成亏损多年，战略融资、申报商保能否带来转机?
8月13日开盘，北海康成股价大涨，截至收盘涨25.75%。 今日早间，公司宣布了战略融资事项以及与百洋医药的独家商业服务协议，后者的附属公司将作为独家合同销售组...
2025-08-13 16:25
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
Aligos Therapeutics appoints Kieron Wesson, PhD as Vice President, Head of CMC, adding his 20+ years of experience to strengthen the company's development efforts in liver and viral diseases, including upcoming studies.
2025-06-18 12:00
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics granted 26,000 stock options to new employees under its 2024 Inducement Plan, exercisable at the June 10 closing price, vesting over four years.
2025-06-13 12:00
首个自研产品将商业化，“罕见病港股第一股”能否迎来业绩转折？
转自：贝壳财经 港股上市公司北海康成制药有限公司（以下简称北海康成）近日发布公告，注射用维拉苷酶β（商品名为戈芮宁）获国家药监局批准上市，成为国内首个自主研发适...
2025-05-29 21:46
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
Aligos Therapeutics将于6月5日下午2点ET参与Jefferies全球医疗健康会议，讨论其针对肝脏和病毒疾病的最佳疗法。
2025-05-29 12:00
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.
2025-03-11 00:59
Aligos Therapeutics Q4 EPS $(13.08) Misses $(2.30) Estimate, Sales $629.00K Beat $433.33K Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(13.08) per share which missed the analyst consensus estimate of $(2.30) by 468.7 percent. This is a 137.82 percent decrease over losses of $(5.50) per
2025-03-10 20:03
